- Home
- RIGL vs ALF Comparison
RIGL vs ALF Comparison
Compare RIGL & ALF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- ALF
- Stock Information
- Founded
- RIGL 1996
- ALF 2024
- Country
- RIGL United States
- ALF United States
- Employees
- RIGL N/A
- ALF N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- ALF
- Sector
- RIGL Health Care
- ALF
- Exchange
- RIGL Nasdaq
- ALF NYSE
- Market Cap
- RIGL 335.5M
- ALF 379.1M
- IPO Year
- RIGL 2000
- ALF 2024
- Fundamental
- Price
- RIGL $21.91
- ALF $10.51
- Analyst Decision
- RIGL Buy
- ALF
- Analyst Count
- RIGL 5
- ALF 0
- Target Price
- RIGL $36.40
- ALF N/A
- AVG Volume (30 Days)
- RIGL 182.1K
- ALF 74.1K
- Earning Date
- RIGL 08-05-2025
- ALF 01-01-0001
- Dividend Yield
- RIGL N/A
- ALF N/A
- EPS Growth
- RIGL N/A
- ALF N/A
- EPS
- RIGL 2.08
- ALF 0.37
- Revenue
- RIGL $203,077,000.00
- ALF N/A
- Revenue This Year
- RIGL $14.41
- ALF N/A
- Revenue Next Year
- RIGL $15.97
- ALF N/A
- P/E Ratio
- RIGL $10.11
- ALF $28.27
- Revenue Growth
- RIGL 70.16
- ALF N/A
- 52 Week Low
- RIGL $8.61
- ALF $9.96
- 52 Week High
- RIGL $29.82
- ALF $10.64
- Technical
- Relative Strength Index (RSI)
- RIGL 66.30
- ALF N/A
- Support Level
- RIGL $19.51
- ALF N/A
- Resistance Level
- RIGL $21.41
- ALF N/A
- Average True Range (ATR)
- RIGL 0.88
- ALF 0.00
- MACD
- RIGL 0.24
- ALF 0.00
- Stochastic Oscillator
- RIGL 96.45
- ALF 0.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ALF CENTURION ACQUISITION CORP
Centurion Acquisition Corp is a blank check company.